Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217339 | 0.90 | SMN1; SMN2 (0.61) | GAATP53HTTHIF1ANPSR1 | |
| SCHEMBL609306 | 0.86 | TP53 (0.59) | TP53HTTHIF1ANPSR1SMN1; SMN2 | |
| SCHEMBL29930365 | 0.86 | TP53 (0.59) | TP53HTTHIF1ANPSR1SMN1; SMN2 | |
| SCHEMBL611715 | 0.81 | F10 (0.57) | TP53HTTHIF1ANPSR1LMNA | |
| SCHEMBL2302983 | 0.80 | GAA (0.61) | GAAHTTSMN1; SMN2LMNAPKM | |
| SCHEMBL2234141 | 0.80 | GAA (0.61) | GAAHTTSMN1; SMN2LMNAPKM | |
| SCHEMBL608919 | 0.80 | F10 (0.58) | TP53HTTHIF1ANPSR1AKR1C3 | |
| SCHEMBL2237998 | 0.79 | GAA (0.60) | GAAHTTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2046118 | 0.76 | POLB (0.61) | GAATP53HTTHIF1ANPSR1 | |
| SCHEMBL8818892 | 0.76 | TDP1 (0.68) | GAAHTTSMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | GAA 3894/4885TP53 26/4885HTT 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.